中新健康丨医药企业热议四中全会公报：我们正经历“质的飞跃”

Core Viewpoint - The 20th Central Committee's Fourth Plenary Session emphasized accelerating high-level technological self-reliance and innovation in the biopharmaceutical industry, which is expected to lead to a qualitative leap in China's biopharmaceutical innovation [1][2]. Group 1: Strategic Direction - The session's report encourages innovation as the primary focus for the biopharmaceutical industry, providing a clear direction for companies engaged in original and cutting-edge technology development [2][4]. - Companies are motivated by the report's emphasis on high-level technological self-reliance, which is seen as a call to pursue original and leading innovations rather than low-level repetitions [2][3]. Group 2: Industry Advantages - China's unique innovation ecosystem is highlighted as a significant advantage, with biopharmaceutical companies leveraging the engineer dividend and exploring deep innovation areas [2][3]. - The country’s data platform and algorithm breakthroughs allow for cost-effective and rapid data collection, enhancing the competitiveness of AI-driven pharmaceutical innovations [3]. Group 3: Global Positioning - Some Chinese biopharmaceutical companies have begun to gain recognition on the global stage, developing innovative drugs that are acknowledged by international academia and industry [4]. - There is a need for more companies to enhance their global clinical development and commercialization capabilities to compete with multinational pharmaceutical firms [4]. Group 4: Policy and Support - The industry calls for supportive policies to foster high-level technological innovation, including financial support and optimized regulatory mechanisms [5]. - Companies are encouraged to take on the responsibility of innovation, increasing R&D investment and focusing on key technology development to enhance domestic biopharmaceutical innovation capabilities [5].